EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Primary epithelioid angiosarcoma of thyroid: A case report and review of literature

Xiaoxia He, Letian Yang, Guorong Yang iD, Weitao Zhang, Li Ma, Haiyun Wang, Fenghua Su, Dunhui Ma, Yankun Li, Li Jiao

International Journal of Immunopathology and Pharmacology · 2026-04 · 40

DOI: 10.1177/03946320261440424 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Immunopathology and Pharmacology, online erschienen am 07.04.2026. Verfasst von Xiaoxia He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Management Center of Chronic Disease, The Second People's Hospital of Lanzhou, Lanzhou, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Hemangiosarcoma, Epithelioid Cells. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epithelioid angiosarcoma (EA) is a malignant tumor of endothelium origin that most commonly arises in the deep soft tissues of extremities but may occasionally be primary in skin, adrenal gland, and bone. A 72-year-old male presented with a painless enlargement of his thyroid for more than 10 days before hospitalization. A walnut-sized mass in the right thyroid was found simultaneously by palpation and Color Doppler Ultrasound. After a total thyroidectomy was performed, a mass with a size of 4.5 cm × 3.5 cm was found at the lower pole of the right thyroid gland. Histologically, the tumor was diffusely distributed in a sheet-like pattern, with tumor cells being epithelioid. There was extensive coagulative necrosis while no components of papillary carcinoma, follicular carcinoma and insular poorly differentiated carcinoma were noticed. CD31 and vimentin were positive for immunostaining. The diagnosis of primary epithelioid angiosarcoma of right thyroid was then given to the patient. Eleven months after the operation, the patient died from brain metastasis. It is suggested that primary epithelioid angiosarcoma of thyroid, as an extremely rare tumor, have no characteristic clinical manifestations, laboratory and imaging examinations, and the diagnosis mainly depend on its unique clinical pathological features. Although extensive surgical resection is the preferred treatment, the prognosis is still very poor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsHemangiosarcomaEpithelioid CellsHumansMaleAgedFatal OutcomeThyroidectomyBrain Neoplasms

Stichwörter der Autor:innen

angiosarcomacase reportclinical pathological featureepithelioidthyroid

Autor:innen und Institutionen

  • Management Center of Chronic Disease, The Second People's Hospital of Lanzhou, Lanzhou, China.
  • School of Intelligent Engineering and Automation, Beijing University of Posts and Telecommunications, Beijing, China.
  • Department of Pathology, San Ai Tang Hospital, Lanzhou, China.
  • Department of Pathology, The People's Hospital of Linxia Hui Autonomous Prefecture, Linxia, China.

ORCID-Profile: Guorong Yang

Zitieren

APA

He, X., Yang, L., Yang, G., Zhang, W., Ma, L., Wang, H., Su, F., Ma, D., Li, Y., & Jiao, L. (2026). Primary epithelioid angiosarcoma of thyroid: A case report and review of literature. International Journal of Immunopathology and Pharmacology, 40. https://doi.org/10.1177/03946320261440424

Vancouver

He X, Yang L, Yang G, Zhang W, Ma L, Wang H, et al. Primary epithelioid angiosarcoma of thyroid: A case report and review of literature. International Journal of Immunopathology and Pharmacology. 2026;40. doi:10.1177/03946320261440424

BibTeX
@article{He2026,
  author = {He, Xiaoxia and Yang, Letian and Yang, Guorong and Zhang, Weitao and Ma, Li and Wang, Haiyun and Su, Fenghua and Ma, Dunhui and Li, Yankun and Jiao, Li},
  title = {Primary epithelioid angiosarcoma of thyroid: A case report and review of literature},
  journal = {International Journal of Immunopathology and Pharmacology},
  year = {2026},
  volume = {40},
  doi = {10.1177/03946320261440424}
}
Kostenlos starten →